Service
DNA and RNA Solid Tumor
Integrated DNA and RNA sequencing to uncover actionable mutations, gene fusions, and expression patterns in solid tumors
Key advantages
-
Dual analysis of DNA and RNA from the same tumor sample
-
Detection of somatic variants, fusions, CNVs, and gene expression profiles
-
Supports clinical decision-making with biomarker-guided therapy selection
-
Applicable to FFPE and fresh-frozen samples
-
Fusion detection even in absence of known breakpoints
-
Expression profiling to support pathway activation and immune status analysis
-
Broad gene panels or custom assays available for tumor-specific insights
-
Supports rare and common solid tumors, including lung, colorectal, breast, prostate, glioma
Technical specifications
-
Sample type: FFPE tissue, fresh-frozen tumor biopsies
-
Nucleic acid extraction: simultaneous DNA and RNA isolation
-
Sequencing type: WES, WGS, TSO500
-
Targeted panels: customizable panels including known cancer drivers
-
Variant detection: SNVs, Indels, CNVs, fusions, splice variants
-
Expression analysis: transcript quantification and pathway enrichment
-
Bioinformatics pipeline: alignment, variant calling, fusion detection, expression matrix
-
Instruments: Illumina NovaSeq, MGI DNBSEQ, and RNA-seq compatible platforms
-
Output files: FASTQ, BAM, VCF, fusion reports, expression tables, annotated results
- Use cases: diagnostics support, therapy selection, translational research, biomarker discovery